Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer

被引:0
|
作者
Xu, T [1 ]
Wang, XF [1 ]
Hou, SK [1 ]
Zhu, JC [1 ]
Zhang, XD [1 ]
Huang, XB [1 ]
机构
[1] Peking Univ, People Hosp, Dept Urol, Beijing 100044, Peoples R China
关键词
prostate cancer; androgens; arteriosclerosis;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To analyze the effect of castration on risk factors for arteriosclerosis of patients with prostate cancer. Methods Thirty patients with primary regional prostate adenocarcinoma limited to the prostate theca were selected in this study. Serum levels of testosterone (T), free testosterone ( FT), dehydroepiandrosterone (DHEA), sex hormone-binding globulin (SHBG), prostatic specific antigen (PSA), triglyceride (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apoprotein alpha(1) (APOalpha(1)) and apoprotein beta (APObeta), insulin, plasma fibrinopeptide A ( FPA), plasminogen activator inhibitor-1 (PAI-1) and fibrinogen were determined just prior to, 1 week and 1, 4 and 8 months after castration. Results T, FT and PSA decreased significantly 1 week after castration (21.12 +/- 15.11 ng/ml vs 383.9 +/- 62.6 ng/ml, P < 0.001; 4.08 +/- 3.29 pmol/L vs 34.11 +/- 11.59 pmol/L, P < 0.001; 14.34 +/- 7.77 ng/ml vs 23.51 +/- 6.57 ng/ml, P = 0.001, respectively) and continued to decrease until reaching their lowest levels 8 months after castration. DHEA and SHBG did not undergo any changes. TG, fasting insulin and glucose, 2-hour insulin and glucose levels were significantly elevated 1 month after castration (1.84 +/- 0.61 mmol/L vs 1.30 +/- 0.40 mmol/L, P < 0.05; 18.16 +/- 5.57 mU/L vs 9.47 +/- 3.81 mU/L, P < 0.05; 4.77 +/- 0.66 mmol/L vs 3.92 +/- 0.34 mmol/L, P < 0. 05; 65.52 +/- 14.78 mU/L vs 36.94 +/- 17.12 mU/L, P < 0.01; 6.98 +/- 0.79 mmol/L vs 6.01 +/- 0.23 mmol/L, P = 0.001, respectively). TC, LDL-C, FPA and PAI-1 levels were elevated 4 months after castration (6.56 +/- 0.99 mmol/L vs; 5.29 +/- 0.75 mmol/L, P < 0.01; 4.09 +/- 0.86 mmol/L vs 3.04 +/- 0.15 mmol/L, P < 0.01; 3.39 +/- 1.67 nmol/L vs 1.48 +/- 0.50 nmol/L, P < 0. 01; 27.02 +/- 5.98 ng/ml vs 21.78 +/- 3.16 ng/ml, P < 0. 05, respectively), continuing to increase after that point. Insulin sensitive index (ISI) decreased significantly 1 month after surgery (-4.42 +/- 0.36 vs - 3.50 +/- 0.39, P < 0.001), and continued to decrease from that point forward. HDL-C, APOal, APOP and fibrinogen remained at pre-operative levels. There was a negative linear correlation between FT and TG, TC, LDL-C, PAI-1, FPA, fasting insulin and glucose, 2-hour insulin and glucose ( r = - 0. 311, - 0.384, - 0.385, - 0.339, - 0.353, - 0.381, - 0.303, - 0.460 and - 0. 395, respectively; P < 0.05). A similar phenomenon occurred with T ( r = - 0.308, - 0.309, - 0.356, - 0. 320, - 0.430, - 0.453, - 0.435, - 0.483 and - 0. 512, respectively; P &LT; 0.05). T and FT were positively associated with ISI ( r = 0. 555 and 0. 501; P &LT; 0.001). Conclusions At 8 months follow-up of the study subjects, we found that lower androgen levels have adverse effects on lipid metabolism, coagulative function and insulin sensitivity, related to arteriosclerosis in men.
引用
收藏
页码:1336 / 1340
页数:5
相关论文
共 50 条
  • [31] Is chemical/surgical castration necessary during docetaxel chemotherapy for castration-resistant prostate cancer?
    Watanabe, Masahito
    Kanao, Kent
    Muramatsu, Hiroyuki
    Morinaga, Shingo
    Kajikawa, Keishi
    Kobayashi, Ikuo
    Nishikawa, Genya
    Kato, Yoshiharu
    Nakamura, Kogenta
    Sumitomo, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] The Effect of Time to Castration Resistance on Overall Survival and Success of Docetaxel Treatment in Castration Resistant Prostate Cancer Patients
    Suer, Evren
    Hamidi, Nurullah
    Akpinar, Cagri
    Gokce, Mehmet Ilker
    Gulpinar, Omer
    Turkolmez, Kadir
    Beduk, Yasar
    Baltaci, Sumer
    UROLOGY JOURNAL, 2019, 16 (05) : 453 - 457
  • [33] Risk factors for prostate cancer
    Patel, Amit R.
    Klein, Eric A.
    NATURE CLINICAL PRACTICE UROLOGY, 2009, 6 (02): : 87 - 95
  • [34] Risk factors for prostate cancer
    Amit R Patel
    Eric A Klein
    Nature Clinical Practice Urology, 2009, 6 : 87 - 95
  • [35] Prognostic factors and response predictors in castration resistant prostate cancer
    Pascual Piedrola, Juan Ignacio
    Hevia Suarez, Mateo
    Ancizu Markert, Francisco Javier
    Garcia Cortes, Angel
    Domenech Lopez, Pablo
    Chiva San Roman, Santiago
    Veils Campillo, Jose Maria
    Diez-Caballero Alonso, Fernando
    Robles Garcia, Jose Enrique
    Rosell Costa, David
    Villacampa Auba, Felipe
    de Fata Chilton, Fernando Ramon
    Nirvana Lopez, Bernardino
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (08): : 704 - 710
  • [36] The effect of risk factors on surgical and oncological results in high-risk prostate cancer: A multicentre study of the urooncology society, Turkey
    Izol, Volkan
    Akdogan, Nebil
    Ozen, Haluk
    Akdogan, Bulent
    Kural, Ali Riza
    Tuna, Mustafa Bilal
    Sozen, Sinan
    Turkeri, Levent
    Tansug, Mustafa Zuhtu
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (08)
  • [37] Effect of dutasteride on castration-resistant prostate cancer
    Azuma, Takeshi
    Matayoshi, Yukihide
    Sato, Yujiro
    Nagase, Yasuhi
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (01) : 133 - 136
  • [38] Risk factors for metastasis in prostate cancer patients: A systematic review
    Susanto, Billy
    Geraldo, Griffin
    Limanto, Jennifer Jesse
    Kurniawan, Andree
    ANNALS OF ONCOLOGY, 2021, 32 : S315 - S315
  • [39] Experience with Octreotide in patients with castration refractory prostate cancer
    Ganov, D. I.
    Varlamov, S. A.
    ONKOUROLOGIYA, 2011, 7 (04): : 71 - 73
  • [40] Enzalutamide for Patients with castration-resistant Prostate Cancer
    Kessing, Richard
    AKTUELLE UROLOGIE, 2020, 51 (01)